Facebook
Twitter
LinkedIn

Media Center

FAST, Fellow and CARB-X Update August 2018
Facebook
Twitter
LinkedIn

FAST & Fellows Round-Up

  • FAST grad (Spring 2015) Magnetic Insight received NIH award of $1.5M Phase II SBIR grant to support the first commercial multimodal preclinical magnetic particle imaging system Read More
  • FAST grad (Fall 2013) Xcell Biosciences announced a collaboration with Carolina BioOncology Institute to further pre-clinical development of true personalized medicine therapies Read More
  • FAST grad (Fall 2016) SciBac received a CARB-X award of up to $3.76 million to develop a novel biotherapeutic to fight deadly Clostridium difficile infections Read More

CARB-X Updates

  • Powered by CARB-X company, ContraFect Corporation announced the pricing of $10 million public offering of common stock Read More
  • Powered by CARB-X company, Tetraphase Pharmaceuticals announced FDA approval of Xerava™ (eravacycline) for complicated intra-abdominal infections (CIAI) Read More Tetraphase also announced a positive CHMP opinion recommending Xerava™ for approval in the EU for CIAI Read More
  • Powered by CARB-X company, Forge Therapeutics achieved CARB-X milestone to advance its LpxC antibiotic to treat urinary tract infections including MDR infections caused by CRE and ESBL Read More
  • Powered by CARB-X company, BugWorks raised $9M Series A funding to take its first-in-class antibiotic into the clinic Read More
  • Powered by CARB-X company, Summit Therapeutics announced it has been awarded an additional $12 million under its contract with BARDA for Phase 3 development program of ridinilazole for the treatment of C. difficile infection Read More
  • Powered by CARB-X company, Iterum Therapeutics initiated SURE 1, a Phase 3 clinical trial of oral sulopenem for treatment of uncomplicated urinary tract infections Read More
  • Powered by CARB-X company, Entasis Therapeutics announced positive topline results from Phase 2 Trial of ETX2514SUL in patients with complicated urinary tract infections including acute pyelonephritis Read More Entasis Therapeutics also filed an S-1 for a proposed $86.3M IPO Read More